ASX - By Stock
|
PAR |
Re:
Ann: PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3
|
|
goldmad
|
482 |
116K |
1 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
482
|
116K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3
|
|
goldmad
|
482 |
116K |
2 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
482
|
116K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3
|
|
goldmad
|
482 |
116K |
0 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
482
|
116K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3
|
|
goldmad
|
482 |
116K |
1 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
482
|
116K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3
|
|
goldmad
|
482 |
116K |
6 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
482
|
116K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3
|
|
goldmad
|
482 |
116K |
0 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
482
|
116K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR RECEIVES POSITIVE RESPONSE FROM US FDA FOR PHASE 3
|
|
goldmad
|
482 |
116K |
6 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
482
|
116K
|
6
|
|
ASX - By Stock
|
BOT |
Re:
Sofdra US Sales Curve
|
|
goldmad
|
112 |
53K |
4 |
13/09/24 |
13/09/24 |
ASX - By Stock
|
112
|
53K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
FDA delay for ph 3 trial approval
|
|
goldmad
|
78 |
32K |
13 |
03/09/24 |
03/09/24 |
ASX - By Stock
|
78
|
32K
|
13
|
|
ASX - By Stock
|
BOT |
Re:
Sofdra US Sales Curve
|
|
goldmad
|
112 |
53K |
6 |
02/09/24 |
02/09/24 |
ASX - By Stock
|
112
|
53K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Mesoblast
|
|
goldmad
|
10 |
3.9K |
3 |
23/08/24 |
23/08/24 |
ASX - By Stock
|
10
|
3.9K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
goldmad
|
4.3K |
3.8M |
3 |
20/08/24 |
20/08/24 |
ASX - By Stock
|
4.3K
|
3.8M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
The BOND of iPPS.
|
|
goldmad
|
1 |
1.1K |
6 |
18/08/24 |
18/08/24 |
ASX - By Stock
|
1
|
1.1K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
imminent means
|
|
goldmad
|
38 |
12K |
0 |
07/08/24 |
07/08/24 |
ASX - By Stock
|
38
|
12K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
imminent means
|
|
goldmad
|
38 |
12K |
0 |
07/08/24 |
07/08/24 |
ASX - By Stock
|
38
|
12K
|
0
|
|
ASX - By Stock
|
BOT |
Re:
BOT - Anything but charting
|
|
goldmad
|
10K |
4.0M |
7 |
06/08/24 |
06/08/24 |
ASX - By Stock
|
10K
|
4.0M
|
7
|
|
ASX - By Stock
|
PAR Biotech |
Re:
Timelines and Capital Requirements
|
|
goldmad
|
4 |
1.8K |
3 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
4
|
1.8K
|
3
|
|
ASX - By Stock
|
PAR Biotech |
Timelines and Capital Requirements
|
|
goldmad
|
4 |
1.8K |
10 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
4
|
1.8K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
goldmad
|
100 |
28K |
6 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
100
|
28K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Sharewise Presentation 22/7/24
|
|
goldmad
|
139 |
41K |
3 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
139
|
41K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Another one bites the dust?
|
|
goldmad
|
11 |
4.2K |
6 |
28/07/24 |
28/07/24 |
ASX - By Stock
|
11
|
4.2K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Sharewise Presentation 22/7/24
|
|
goldmad
|
139 |
41K |
1 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
139
|
41K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Sharewise Presentation 22/7/24
|
|
goldmad
|
139 |
41K |
3 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
139
|
41K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
goldmad
|
4.4K |
2.0M |
6 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
6
|
|
ASX - By Stock
|
PAR |
Re:
PARate Day 2024 - scurvy dogs o' the ASX
|
|
goldmad
|
124 |
40K |
0 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
124
|
40K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
goldmad
|
706 |
257K |
8 |
29/06/24 |
29/06/24 |
ASX - By Stock
|
706
|
257K
|
8
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
goldmad
|
14K |
5.3M |
3 |
25/06/24 |
25/06/24 |
ASX - By Stock
|
14K
|
5.3M
|
3
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
goldmad
|
14K |
5.3M |
8 |
25/06/24 |
25/06/24 |
ASX - By Stock
|
14K
|
5.3M
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
goldmad
|
706 |
257K |
1 |
22/06/24 |
22/06/24 |
ASX - By Stock
|
706
|
257K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
goldmad
|
706 |
257K |
1 |
22/06/24 |
22/06/24 |
ASX - By Stock
|
706
|
257K
|
1
|
|
ASX - By Stock
|
BOT |
Re:
Ann: Botanix $70 Million Institutional Capital Raising
|
|
goldmad
|
267 |
103K |
7 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
267
|
103K
|
7
|
|
ASX - By Stock
|
BOT |
Re:
Ann: FDA Approves Sofdra
|
|
goldmad
|
554 |
203K |
11 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
554
|
203K
|
11
|
|
ASX - By Stock
|
BOT |
Re:
Ann: FDA Approves Sofdra
|
|
goldmad
|
554 |
203K |
5 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
554
|
203K
|
5
|
|
ASX - By Stock
|
BOT |
Re:
Ann: FDA Approves Sofdra
|
|
goldmad
|
554 |
203K |
13 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
554
|
203K
|
13
|
|
ASX - By Stock
|
BOT |
Re:
Ann: FDA Approves Sofdra
|
|
goldmad
|
554 |
203K |
12 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
554
|
203K
|
12
|
|
ASX - By Stock
|
BOT |
Re:
BOT - Anything but charting
|
|
goldmad
|
10K |
4.0M |
5 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
10K
|
4.0M
|
5
|
|
ASX - By Stock
|
BOT |
Re:
Sofdra US Sales Curve
|
|
goldmad
|
112 |
53K |
2 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
112
|
53K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
goldmad
|
4.4K |
2.0M |
3 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
4.4K
|
2.0M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
goldmad
|
706 |
257K |
1 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
706
|
257K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
goldmad
|
706 |
257K |
4 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
706
|
257K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
goldmad
|
706 |
257K |
4 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
706
|
257K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Employee Performance Rights Plan Issue
|
|
goldmad
|
12 |
3.3K |
1 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
12
|
3.3K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
goldmad
|
1.4K |
381K |
5 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
1.4K
|
381K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
goldmad
|
1.4K |
381K |
2 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
1.4K
|
381K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
goldmad
|
327 |
110K |
3 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
327
|
110K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
goldmad
|
327 |
110K |
6 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
327
|
110K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
goldmad
|
236 |
81K |
5 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
236
|
81K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
goldmad
|
236 |
81K |
7 |
04/02/24 |
04/02/24 |
ASX - By Stock
|
236
|
81K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
goldmad
|
1.2K |
421K |
2 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
1.2K
|
421K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
goldmad
|
1.2K |
421K |
0 |
11/01/24 |
11/01/24 |
ASX - By Stock
|
1.2K
|
421K
|
0
|
|